Cargando…

A Poor-Quality Generic Drug for the Treatment of Visceral Leishmaniasis: A Case Report and Appeal

Detalles Bibliográficos
Autores principales:	Dorlo, Thomas P. C., Eggelte, Teunis A., Schoone, Gerard J., de Vries, Peter J., Beijnen, Jos H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Viewpoints
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3362618/ https://www.ncbi.nlm.nih.gov/pubmed/22666507 http://dx.doi.org/10.1371/journal.pntd.0001544

Ejemplares similares

Dynamics of Parasite Clearance in Cutaneous Leishmaniasis Patients Treated with Miltefosine
por: Dorlo, Thomas P. C., et al.
Publicado: (2011)

Anticipating visceral leishmaniasis epidemics due to the conflict in Northern Ethiopia
por: Boodman, Carl, et al.
Publicado: (2023)

Low antileishmanial drug exposure in HIV-positive visceral leishmaniasis patients on antiretrovirals: an Ethiopian cohort study
por: Kip, Anke E, et al.
Publicado: (2021)

Visceral Leishmaniasis as an AIDS Defining Condition: Towards Consistency across WHO Guidelines
por: van Griensven, Johan, et al.
Publicado: (2014)

Visceral Leishmaniasis and Arsenic: An Ancient Poison Contributing to Antimonial Treatment Failure in the Indian Subcontinent?
por: Perry, Meghan R., et al.
Publicado: (2011)

Visceral Leishmaniasis Relapse in HIV Patients—A Role for Myeloid-Derived Suppressor Cells?
por: Van den Bergh, Rafael, et al.
Publicado: (2014)

One More Death from Visceral Leishmaniasis Has Gone by Unnoticed. What Can Be Done?
por: Matlashewski, Greg, et al.
Publicado: (2013)

Characterizing the non-linear pharmacokinetics of miltefosine in paediatric visceral leishmaniasis patients from Eastern Africa
por: Palić, Semra, et al.
Publicado: (2020)

Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis
por: Kip, Anke E., et al.
Publicado: (2018)

Systematic Review of Host-Mediated Activity of Miltefosine in Leishmaniasis through Immunomodulation
por: Palić, Semra, et al.
Publicado: (2019)

Evaluation of systemic impact of tricuspid regurgitation: an appeal for the notion of tricuspid regurgitation syndrome
por: Lu, Fanglin, et al.
Publicado: (2023)

Blood Parasite Load as an Early Marker to Predict Treatment Response in Visceral Leishmaniasis in Eastern Africa
por: Verrest, Luka, et al.
Publicado: (2021)

Long-lasting Insecticidal Nets to Prevent Visceral Leishmaniasis in the Indian Subcontinent; Methodological Lessons Learned from a Cluster Randomised Controlled Trial
por: Picado, Albert, et al.
Publicado: (2015)

Prescribing generics: All in a name
por: Roy, Vandana, et al.
Publicado: (2018)

No Time to Waste: Real-World Repurposing of Generic Drugs as a Multifaceted Strategy Against COVID-19
por: Rogosnitzky, Moshe, et al.
Publicado: (2020)

The yin and yang of leishmaniasis control
por: Kamhawi, Shaden
Publicado: (2017)

Policy and Ethical Considerations for Widespread Utilization of Generic Orthopedic Implants
por: Pean, Christian A., et al.
Publicado: (2019)

Application of Direct Agglutination Test (DAT) and Fast Agglutination Screening Test (FAST) for sero-diagnosis of visceral leishmaniasis in endemic area of Minas Gerais, Brazil
por: Silva, Eduardo S, et al.
Publicado: (2005)

Drug Resistance in Visceral Leishmaniasis
por: Maltezou, Helena C.
Publicado: (2010)

Safety and Efficacy of Single Dose versus Multiple Doses of AmBisome® for Treatment of Visceral Leishmaniasis in Eastern Africa: A Randomised Trial
por: Khalil, Eltahir A. G., et al.
Publicado: (2014)

Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients
por: Adriaensen, Wim, et al.
Publicado: (2018)

Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study
por: Dorlo, Thomas P C, et al.
Publicado: (2017)

Failure of Miltefosine Treatment for Visceral Leishmaniasis in Children and Men in South-East Asia
por: Ostyn, Bart, et al.
Publicado: (2014)

A new perspective on cutaneous leishmaniasis—Implications for global prevalence and burden of disease estimates
por: Bailey, Freddie, et al.
Publicado: (2017)

Rewriting the history of leishmaniasis in Sri Lanka: An untold story since 1904
por: Nuwangi, Hasara, et al.
Publicado: (2022)

Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial
por: Wasunna, Monique, et al.
Publicado: (2016)

Development and Evaluation of a Novel Loop-Mediated Isothermal Amplification Assay for Diagnosis of Cutaneous and Visceral Leishmaniasis
por: Adams, Emily Rebecca, et al.
Publicado: (2018)

Visceral leishmaniasis
por: Sundar, Shyam
Publicado: (2015)

Visceral leishmaniasis: Experimental models for drug discovery
por: Gupta, Suman, et al.
Publicado: (2011)

Evaluating drug resistance in visceral leishmaniasis: the challenges
por: HENDRICKX, S, et al.
Publicado: (2018)

Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis Patients
por: Verrest, Luka, et al.
Publicado: (2021)

Rectal Cancer in West China: Younger Onset, Poor Survival, and Poor Compliance
por: Fang, Chao, et al.
Publicado: (2021)

Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs
por: Kip, Anke E., et al.
Publicado: (2017)

An Appeal to Appealers
Publicado: (1895)

Congenital Visceral Leishmaniasis
por: Boehme, Catharina C., et al.
Publicado: (2006)

Immunity to Visceral Leishmaniasis
por: Ali, Nahid, et al.
Publicado: (2012)

Treatment of Visceral Leishmaniasis
por: Moore, E M, et al.
Publicado: (2010)

Immunobiology of visceral leishmaniasis
por: Kumar, Rajiv, et al.
Publicado: (2012)

Epidemiology of visceral leishmaniasis
por: Ready, Paul D
Publicado: (2014)

The reemergence of visceral leishmaniasis in Brazil.
por: Arias, J R, et al.
Publicado: (1996)

Cannot write session to /tmp/vufind_sessions/sess_ib1lrujvg8g65ua9msdqeo1sqj